199 Biotechnologies

199 Biotechnologies is a preclinical-stage biotechnology company developing epigenetic reprogramming and senolytic therapies targeting cancer and age-related disease.

Its lead programme applies partial cellular reprogramming to modify the behaviour of glioblastoma cells, reducing malignancy and reactivating natural cell death pathways without targeting healthy tissue.

A separate programme is investigating Procyanidin C1, a grape seed-derived polyphenol, as a senolytic compound for healthspan extension.

The company also operates a diagnostics service offering senescence markers and biological age biomarker testing.